Intelligent Bio Solutions Drives Global Growth Through Multilingual Digital Expansion
Intelligent Bio Solutions (NASDAQ: INBS) has launched three new localized websites in Arabic, Italian, and Spanish as part of its global expansion strategy. This digital expansion provides access to markets representing over 1.4 billion people across Europe, the Middle East, and Latin America.
The company's fingerprint sweat-based drug screening system, which provides results in under 10 minutes, currently serves over 400 active accounts in 19 countries. The Latin American drug screening market alone is projected to reach $1.1 billion by 2030. The multilingual rollout complements INBS' recent advancements in multilingual reader functionality and aims to strengthen distributor relationships and accelerate market penetration in non-English speaking regions.
Intelligent Bio Solutions (NASDAQ: INBS) ha lanciato tre nuovi siti web localizzati in arabo, italiano e spagnolo come parte della sua strategia di espansione globale. Questa espansione digitale offre accesso a mercati che rappresentano oltre 1,4 miliardi di persone in Europa, Medio Oriente e America Latina.
Il sistema di screening dei farmaci basato sul sudore delle impronte digitali dell'azienda, che fornisce risultati in meno di 10 minuti, serve attualmente oltre 400 account attivi in 19 paesi. Solo il mercato latinoamericano dello screening dei farmaci è previsto raggiungere un valore di 1,1 miliardi di dollari entro il 2030. Il lancio multilingue integra i recenti progressi di INBS nella funzionalità del lettore multilingue e mira a rafforzare le relazioni con i distributori e accelerare la penetrazione del mercato nelle regioni non anglofone.
Intelligent Bio Solutions (NASDAQ: INBS) ha lanzado tres nuevos sitios web localizados en árabe, italiano y español como parte de su estrategia de expansión global. Esta expansión digital ofrece acceso a mercados que representan a más de 1.400 millones de personas en Europa, Medio Oriente y América Latina.
El sistema de detección de drogas basado en sudor de huellas dactilares de la compañía, que proporciona resultados en menos de 10 minutos, actualmente atiende a más de 400 cuentas activas en 19 países. Solo el mercado latinoamericano de detección de drogas se proyecta alcanzar 1.100 millones de dólares para 2030. El despliegue multilingüe complementa los recientes avances de INBS en la funcionalidad de lectores multilingües y busca fortalecer las relaciones con distribuidores y acelerar la penetración en mercados de habla no inglesa.
Intelligent Bio Solutions (NASDAQ: INBS)는 글로벌 확장 전략의 일환으로 아랍어, 이탈리아어, 스페인어로 현지화된 세 개의 새로운 웹사이트를 출시했습니다. 이 디지털 확장은 유럽, 중동, 라틴 아메리카 지역의 14억 명 이상의 인구에 접근할 수 있게 합니다.
회사의 지문 땀 기반 약물 검사 시스템은 10분 이내에 결과를 제공하며, 현재 19개국에서 400개 이상의 활성 계정에 서비스를 제공하고 있습니다. 라틴 아메리카 약물 검사 시장만 해도 2030년까지 11억 달러에 이를 것으로 예상됩니다. 다국어 롤아웃은 INBS의 다국어 리더 기능의 최근 발전을 보완하며, 유통업체와의 관계를 강화하고 비영어권 지역에서 시장 침투를 가속화하는 것을 목표로 합니다.
Intelligent Bio Solutions (NASDAQ : INBS) a lancé trois nouveaux sites web localisés en arabe, italien et espagnol dans le cadre de sa stratégie d'expansion mondiale. Cette expansion numérique offre un accès à des marchés représentant plus de 1,4 milliard de personnes en Europe, au Moyen-Orient et en Amérique latine.
Le système de dépistage de drogues basé sur la sueur des empreintes digitales de l'entreprise, qui fournit des résultats en moins de 10 minutes, dessert actuellement plus de 400 comptes actifs dans 19 pays. Le marché latino-américain du dépistage de drogues seul devrait atteindre 1,1 milliard de dollars d'ici 2030. Le déploiement multilingue complète les récentes avancées d'INBS dans la fonctionnalité de lecteur multilingue et vise à renforcer les relations avec les distributeurs et à accélérer la pénétration du marché dans les régions non anglophones.
Intelligent Bio Solutions (NASDAQ: INBS) hat im Rahmen seiner globalen Expansionsstrategie drei neue lokalisierte Websites in Arabisch, Italienisch und Spanisch gestartet. Diese digitale Erweiterung ermöglicht den Zugang zu Märkten mit über 1,4 Milliarden Menschen in Europa, dem Nahen Osten und Lateinamerika.
Das auf Schweiß basierende Drogenscreening-System des Unternehmens, das Ergebnisse in unter 10 Minuten liefert, betreut derzeit über 400 aktive Konten in 19 Ländern. Allein der lateinamerikanische Drogenscreening-Markt wird bis 2030 voraussichtlich 1,1 Milliarden US-Dollar erreichen. Die mehrsprachige Einführung ergänzt die jüngsten Fortschritte von INBS bei der mehrsprachigen Leserfunktionalität und zielt darauf ab, die Beziehungen zu Vertriebspartnern zu stärken und die Marktdurchdringung in nicht-englischsprachigen Regionen zu beschleunigen.
- Expansion into markets representing 1.4 billion potential customers
- Strong existing presence with 400+ active accounts across 19 countries
- Access to Latin American drug screening market projected at $1.1B by 2030
- Enhanced multilingual capabilities to facilitate faster market penetration
- None.
Insights
INBS launches multilingual websites targeting 1.4B people across high-growth markets, creating infrastructure for global expansion.
Intelligent Bio Solutions' launch of Arabic, Italian, and Spanish websites represents a strategic move to expand commercial reach across Europe, the Middle East, and Latin America—regions collectively representing over 1.4 billion people. This localization effort extends beyond mere translation, functioning as infrastructure for potential market penetration in high-growth regions.
The timing aligns strategically with their recent enhancements to multilingual reader functionality, demonstrating a coordinated approach to product development and market accessibility. By removing language barriers, INBS addresses a fundamental obstacle to adoption in non-English speaking markets, particularly important for health and safety products where precision and clarity are essential.
The Latin American drug screening market presents a quantifiable opportunity, projected to reach $1.1 billion by 2030, with Spanish serving as the official language in 20 countries across the region. Similarly, the Gulf Cooperation Council countries' strengthening enforcement of workplace safety standards creates natural demand drivers for compliant screening solutions in Arabic-speaking regions.
With 400 active accounts across 19 countries already established, this digital expansion builds upon existing international momentum. The company's fingerprint sweat-based drug screening system offers a dignified alternative to traditional testing methods, with results in under ten minutes—potentially appealing in markets where workplace testing is increasing but cultural sensitivities around traditional methods exist.
While this website launch represents early-stage market development rather than immediate revenue generation, it establishes necessary foundational elements for distributor relationship development and lead generation in previously underserved regions.
Arabic, Italian, and Spanish-language websites unlock commercial access to regions representing over 1.4 billion people
Multilingual rollout aligns with product readiness and accelerates international sales pipeline development
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the launch of three new localized websites in Arabic, Italian, and Spanish. This rollout supports the Company's global growth plans and international sales expansion by opening digital and commercial access to some of the world's fastest-growing, high-demand regions for workplace safety and compliance solutions.
The newly launched websites form part of INBS' broader localization strategy, ensuring the business is operationally ready and market-aligned to capture new revenue opportunities across Europe, the Middle East, and Latin America. Collectively, these regions represent a combined population of over 1.4 billion people1.
"This is not just a translation project; it's a commercial growth engine," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "By localizing our online presence and sales infrastructure to make it ready for use by customers across the globe, we are building scalable access to high-potential markets. These initiatives are the foundation for strengthening distributor relationships, increasing lead generation, and facilitating faster market penetration worldwide."
The Company has already seen strong interest from international partners following recent advancements in multilingual reader functionality, which enables its fingerprint sweat-based drug screening system, a portable, hygienic, and dignified alternative to urine or saliva testing, to be accessible and deployable in non-English speaking environments.
INBS has identified strong growth opportunities across Latin America, the Middle East, and Southern Europe. In Latin America, the drug screening market is projected to reach USD 1.1 billion by 20302, with Spanish serving as the official language in 20 countries across the region. Meanwhile, Gulf Cooperation Council (GCC) countries continue to strengthen enforcement of workplace safety standards, driving demand for compliant screening solutions in the Middle East.
The new websites are expected to strengthen inbound demand and accelerate conversion across distribution and sales channels by removing language barriers and aligning with regional expectations. They further complement the Company's ongoing commercial initiatives, including expansion of its global distributor network and increased investment in digital lead generation and localization infrastructure. The new websites can be accessed through INBS' global product website at www.intelligentfingerprinting.com.
INBS’ Intelligent Fingerprinting Drug Screening System is designed to detect recent drug use through fingerprint sweat analysis, providing results in under ten minutes. With over 400 active accounts in 19 countries, INBS continues to lead the evolution of drug screening technology, serving industries including construction, manufacturing, transport, and logistics.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc/
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
Hyperlinks and website references in this release are provided for convenience only, and do not incorporate the referenced content into this release.
1 United Nations, 2024. World Population Prospects 2024, Department of Economic and Social Affairs, Population Division. Available at: https://population.un.org/wpp/
2 Grand View Research 2025. Latin America Drug Screening Market Size & Outlook. Available at: https://www.grandviewresearch.com/horizon/outlook/drug-screening-market/latin-america
FAQ
What is INBS's global expansion strategy in 2025?
How many active accounts does Intelligent Bio Solutions (INBS) have globally?
What is the projected size of the Latin American drug screening market by 2030?
How does INBS's fingerprint drug screening system work?
Which industries does INBS's drug screening technology serve?
